Product Detail

 Home / Product Detail

Rabifeel-20

Rabeprazole Sodium I.P

Rabifeel 20 (Rabeprazole) is a  proton pump inhibitor that suppresses  gastric acid production in the stomach. It has several medical uses: the management of conditions that involve excess gastric acid production (e.g.  Zollinger–Ellison syndrome), conditions that are worsened by gastric acid (e.g. ulcerations of the gastrointestinal tract), and conditions involving prolonged exposure to gastric acid (e.g. symptomatic  gastroesophageal reflux disease).

Rabeprazole's adverse effects tend to be mild but can be serious, including deficiencies in essential nutrients, rare incidences of liver and bone damage, and dangerous rashes. Rabeprazole can theoretically contribute to numerous  drug interactions, mediated both through its metabolic properties and its direct effect on acid in the  stomach, though its potential for clinically meaningful drug interactions is low.

Like other medications in the proton pump inhibitor class, rabeprazole's mechanism of action involves the permanent inhibition of proton pumps in the stomach, which are responsible for gastric acid production. Rabeprazole has a number of chemical  metabolites, though it is primarily degraded by non-enzymatic metabolism and excreted in the urine. Genetic differences in a person's drug-metabolizing  enzymes may affect a person's response to rabeprazole therapy, though this is unlikely in comparison to other proton pump inhibitors..

Medical uses

Rabeprazole, like other  proton pump inhibitors such as  omeprazole, is used for the purposes of gastric acid suppression. This effect is beneficial for the treatment and prevention of conditions in which gastric acid directly worsens symptoms, such as duodenal and gastric ulcers. In the setting of  gastroesophageal reflux disease (GERD), whose pathophysiology is characterized by prolonged exposure to gastric acid in the esophagus (often due to changes in stomach and/or esophagus anatomy, such as those induced by abdominal obesity), acid suppression can provide symptomatic relief. Acid suppression is also useful when gastric production of acid is increased, including conditions with excess gastric acid secretion (hypersecretory conditions) like  Zollinger-Ellison syndrome, multiple endocrine  adenomas, and systemic  mastocytosis.

Rabeprazole is also useful alongside antibiotic therapy for the treatment of the pathogen  Helicobacter pylori, which otherwise thrives in acidic environments. Notably, H. pylori eradication with antibiotics and rabeprazole was also shown to prevent development of second  gastric cancer in a  randomized trial in high-risk  South Korean patients with early stomach cancer treated by  endoscopy.

Thus, rabeprazole is  FDA approved for